AstraZeneca Denies Unjust Enrichment In Cancer Drug Row
By Joanne Faulkner ( September 3, 2021, 1:58 PM BST) -- AstraZeneca has doubled down on claims that it is owed unpaid royalties by U.S. drugmaker Tesaro from sales of a blockbuster cancer drug after the pharmaceutical giant was hit with a $3.6 million counterclaim....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.